Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care

High-intensity end-of-life (EOL) care improves neither cancer patients' survival nor quality of life. We assessed the incidence of and factors associated with aggressiveness of care of lung cancer patients and the impacts of aggressiveness of care in EOL-care costs. Despite the growing attention to providing appropriate EOL care, 57% of the deceased LC patients had at least one EOL-care aggressiveness indicator. Background: Results of previous studies demonstrated that high-intensity end-of-life (EOL) care improves neither cancer patients' survival nor quality of life. Our objective was to assess the incidence of and factors associated with aggressiveness of care during the last 30 days of life (DOL) of lung cancer (LC) patients and the impacts of aggressiveness of care in EOL-care costs. Patients and Methods: Using French national hospital database, all patients with LC who died between January 1, 2010, and December 31, 2011, or between January 1, 2015, and January 31, 2016, were included. EOL-care aggressiveness was assessed using the following criteria: chemotherapy administered within the last 14 DOL; more than one hospitalization within the last 30 DOL; admission to the intensive care unit within the last 30 DOL; and palliative care initiated < 3 days before death. Expenditures were limited to direct costs, from a health care payer's perspective. Results: Among 79,746 adult LC patients identified; 57% had at least one indicator of EOL-care aggressiveness (49% repeated hospitalizations, 12% intensive care unit admissions, 9% chemotherapy, 5% palliative care). It increased significantly between the 2 periods (56% vs. 58%, P < .001). Young age, male sex, shorter time since diagnosis, comorbidities, no malnutrition, type of care facility other than general hospital, social deprivation, and low-density population were independently associated with having one or more indicator of aggressive EOL care. The mean EOL cost was euro8152 +/- 5117 per patient, but the cost was significantly higher for patients with at least one EOL-care aggressiveness criterion (euro9480 vs. euro6376, P < .001). Conclusion: In France, a majority of LC patients had at least one criterion of aggressive EOL care that had a major economic impact on the health care system.